PMID- 29962282
OWN - NLM
STAT- MEDLINE
DCOM- 20190422
LR  - 20211204
IS  - 1563-5279 (Electronic)
IS  - 0020-7454 (Linking)
VI  - 129
IP  - 2
DP  - 2019 Feb
TI  - Rapamycin inhibits activation of AMPK-mTOR signaling pathway-induced Alzheimer's 
      disease lesion in hippocampus of rats with type 2 diabetes mellitus.
PG  - 179-188
LID - 10.1080/00207454.2018.1491571 [doi]
AB  - BACKGROUND: Type 2 diabetes mellitus (T2DM) is strongly correlated with 
      Alzheimer's disease (AD). Rapamycin has important uses in oncology, cardiology 
      and transplantation medicine. This study aims to investigate effects of rapamycin 
      on AD in hippocampus of T2DM rat by AMPK/mTOR signaling pathway. METHODS: Morris 
      water maze test was applied to evaluate the learning and memory abilities. The 
      fasting plasma glucose (FBG), glycosylated haemoglobin, total cholesterol, 
      triglyceride and serum insulin level were measured. RT-qPCR and Western blot 
      analysis were performed to test expression of AMPK and mTOR. Immunohistochemistry 
      was used to detect the Abeta deposition and immunoblotting to test the total tau, 
      p-tau and Abeta precursor APP expressions. RESULTS: After treated with rapamycin, 
      T2DM rats and rats with T2DM and AD showed increased learning-memory ability, and 
      decreased levels of FBG, glycosylated hemoglobin, total cholesterol, triglyceride 
      and serum insulin, decreased expression of APP and p-tau, increased AMPK mRNA 
      expression and p-AMPK and decreased Abeta deposition, mTOR mRNA expression and 
      p-mTOR. CONCLUSION: The study demonstrated that rapamycin reduces the risk of AD 
      in T2DM rats and inhibits activation of AMPK-mTOR signaling pathway, thereby 
      improving AD lesion in hippocampus of T2DM rats.
FAU - Sun, Qin
AU  - Sun Q
AD  - a Department of Geratology, Center of Diabetes Mellitus, Sichuan Academy of 
      Medical Sciences and Sichuan Provincial People's Hospital, School of Medicine , 
      University of Electronic Science and Technology of China , Chengdu , Sichuan 
      Province , PR China.
FAU - Wei, Ling-Ling
AU  - Wei LL
AD  - b Department of Organ Transplantation , Center of Diabetes Mellitus, Sichuan 
      Academy of Medical Sciences and Sichuan Provincial People's Hospital, School of 
      Medicine, University of Electronic Science and Technology of China , Chengdu, 
      Sichuan Province , PR China.
FAU - Zhang, Min
AU  - Zhang M
AD  - c Department of Geratology , Sichuan Academy of Medical Sciences and Sichuan 
      Provincial People's Hospital , Chengdu , PR China.
FAU - Li, Ting-Xin
AU  - Li TX
AD  - d Department of General Medicine , Health Management Center, Sichuan Academy of 
      Medical Sciences and Sichuan Provincial People's Hospital , Chengdu , PR China.
FAU - Yang, Chun
AU  - Yang C
AD  - e Department of Gastrointestinal Surgery , Center of Diabetes Mellitus, Sichuan 
      Academy of Medical Sciences and Sichuan Provincial People's Hospital, School of 
      Medicine, University of Electronic Science and Technology of China, Chengdu , 
      Chengdu , PR China.
FAU - Deng, Shao-Ping
AU  - Deng SP
AD  - b Department of Organ Transplantation , Center of Diabetes Mellitus, Sichuan 
      Academy of Medical Sciences and Sichuan Provincial People's Hospital, School of 
      Medicine, University of Electronic Science and Technology of China , Chengdu, 
      Sichuan Province , PR China.
FAU - Zeng, Qing-Cui
AU  - Zeng QC
AUID- ORCID: 0000-0001-8114-1363
AD  - c Department of Geratology , Sichuan Academy of Medical Sciences and Sichuan 
      Provincial People's Hospital , Chengdu , PR China.
LA  - eng
PT  - Journal Article
DEP - 20181105
PL  - England
TA  - Int J Neurosci
JT  - The International journal of neuroscience
JID - 0270707
RN  - 0 (Amyloid beta-Peptides)
RN  - 0 (Amyloid beta-Protein Precursor)
RN  - 0 (Mapt protein, rat)
RN  - 0 (tau Proteins)
RN  - EC 2.7.1.1 (mTOR protein, rat)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - EC 2.7.11.31 (AMP-Activated Protein Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - AMP-Activated Protein Kinases/*metabolism
MH  - Alzheimer Disease/complications/*metabolism/*prevention & control
MH  - Amyloid beta-Peptides/metabolism
MH  - Amyloid beta-Protein Precursor/metabolism
MH  - Animals
MH  - Diabetes Mellitus, Type 2/complications/*metabolism
MH  - Disease Models, Animal
MH  - Hippocampus/drug effects/*metabolism/pathology
MH  - Male
MH  - Maze Learning/drug effects
MH  - Phosphorylation
MH  - Rats, Sprague-Dawley
MH  - Signal Transduction
MH  - Sirolimus/*administration & dosage
MH  - TOR Serine-Threonine Kinases/*metabolism
MH  - tau Proteins/metabolism
OTO - NOTNLM
OT  - AMPK/mTOR signaling pathway
OT  - Alzheimer disease
OT  - Rapamycin
OT  - type 2 diabetes mellitus
EDAT- 2018/07/03 06:00
MHDA- 2019/04/23 06:00
CRDT- 2018/07/03 06:00
PHST- 2018/07/03 06:00 [pubmed]
PHST- 2019/04/23 06:00 [medline]
PHST- 2018/07/03 06:00 [entrez]
AID - 10.1080/00207454.2018.1491571 [doi]
PST - ppublish
SO  - Int J Neurosci. 2019 Feb;129(2):179-188. doi: 10.1080/00207454.2018.1491571. Epub 
      2018 Nov 5.